Pharmaceuticals
Price
$16.70
+3.21%Market Cap
$18.68B
Day High
$16.74
Day Low
$16.27
Viatris (VTRS) reported Q1 FY2026 revenue of $3.52B (+8.1% YoY), driven by top-line growth, but gross margin compressed to 32.9% as cost of revenue rose faster than sales, while operating loss narrowed dramatically to -$79.7M versus -$2.88B a year ago, and EPS turned positive at $0.15 versus -$2.55.
Key risk: Gross Margin Compression
Gross margin declined approximately 280 basis points YoY to 32.9% as cost of revenue grew at 12.7%, nearly 1.6x the pace of revenue growth at 8.1%. Sustained cost inflation in manufacturing, raw materials, or product mix shifts could further erode profitability if pricing power remains limited in the generics and branded pharmaceutical markets.
Other Pharmaceuticals companies